CXCL2 and neoplasm: We assessed the mRNA expression levels of ELR+CXCLs (CXCL1, CXCL2, CXCL3, CXCL5, CXCL7 and CXCL8) in tumor of ccRCC patients who received treatment with ICIs (nivolumab or nivolumab + ipilimumab, n = 237), as well as everolimus (Fig. 1a-c, Table 1, n = 130), with two distinct cohorts: our cohort (n = 56) and the published cohort (n = 181, [21]).